0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Genomic Rearrangements in Unusual and Atypical Melanocytic Neoplasms

Thomas Wiesner, MD1,2
[+] Author Affiliations
1Memorial Sloan-Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York City, New York
2Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
JAMA Dermatol. 2016;152(3):260-262. doi:10.1001/jamadermatol.2015.3501.
Text Size: A A A
Published online

Extract

Melanocytes can give rise to a variety of benign and malignant neoplasms that are characterized by distinct clinical features, histopathological appearances, and biological behavior. In most melanocytic lesions, the clinical and histopathological distinction between benign (melanocytic nevus) and malignant (melanoma) is relatively easy. However, there exist unusual melanocytic neoplasms whose biological behavior can be difficult to predict with certainty owing to their ambiguous clinical and pathological features. This may lead to underdiagnosis or overdiagnosis of melanoma, or to diagnosis as “melanocytic tumor of uncertain malignant potential” or “melanocytic lesion with severe atypia.” The lack of agreement, even among experts, in determining the biological behavior of these lesions is well documented in the medical literature.1

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.
Frequent Genomic Aberrations in Cutaneous Melanocytic Neoplasms

A, Common acquired nevi usually show BRAF hotspot mutations; congenital nevi NRAS hotspot mutations. B, Cutaneous melanoma show BRAF hotspot mutations (BRAF subtype) in about 50%; NRAS, HRAS, or KRAS mutations (RAS subtype) in 25%; and NF1 (NF1 subtype) loss 10% of cases. The “triple wild-type melanoma” subtype is a heterogeneous subgroup of melanoma with infrequent driver mutations, such as KIT, GNAQ/GNA11, CTNNB1, or genomic rearrangements. C, A third very heterogeneous group of melanocytic tumors includes rare entities of melanocytic neoplasm, such as blue nevi and related neoplasms; spitzoid lesions; deep-penetrating nevi; or pigmented-epithelioid melanocytoma. This heterogeneous subgroup shows a pattern of genomic aberrations very different from melanoma or common acquired and congenital nevi, underlining that these melanocytic lesions are biologically distinct. Blue nevi frequently harbor mutations of GNAQ, and less often of GNA11. Spitzoid neoplasms show translocations involving the kinases ALK, ROS1, NTRK1, BRAF, RET, and MET in up to 50% of cases. Desmoplastic Spitz nevi frequently show HRAS mutations. Spitzoid lesions with large epithelioid cells, often combined with a regular nevoid melanocytes, often show loss of BAP1 and are associated with a hereditary tumor predisposition syndrome.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

536 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
Jobs
brightcove.createExperiences();